Diamyd initiates closure of US Phase III study

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd® and to initiate closure of the study.Following consultation with the US Food and Drug Administration (FDA), Diamyd Medical has decided to suspend dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd®. Study closure activities will commence promptly. The decision follows a blinded review of the efficacy data collected to date in the study as well as the previously reported negative outcome of a European Phase III study of the